Table 1. . Patient demographics.
| Demographics | Included in any analysis (n = 460) | Baseline estrogens analysis (n = 438) | On-treatment estrogen analysis (n = 378) |
|---|---|---|---|
| Age (years) | 59.24 (8.79) | 59.41 (8.67) | 59.80 (8.49) |
| Race: | |||
| – White | 406 (88.3%) | 387 (88.4%) | 334 (88.4%) |
| – Black | 42 (9.1%) | 40 (9.1%) | 34 (9.0%) |
| – Other | 12 (2.6%) | 11 (2.5%) | 10 (2.6%) |
| BMI (kg/m2) | 29.92 (6.47) | 29.97 (6.50) | 30.01 (6.51) |
| Prior treatment: | |||
| – Tamoxifen | 166 (36.1%) | 154 (35.2%) | 130 (34.4%) |
| – HRT | 226 (29.1%) | 218 (49.8%) | 193 (51.1%) |
| SLCO1B1*5 genotype: | |||
| – SLCO1B1*1/*1 | 334 (72.6%) | 323 (73.7%) | 282 (74.6%) |
| – SLCO1B1*1/*5 | 119 (25.9%) | 108 (24.7%) | 91 (24.1%) |
| – SLCO1B1*5/*5 | 7 (1.5%) | 7 (1.6%) | 5 (1.3%) |
| rs10841753 genotype: | |||
| – Wild-type (TT) | 309 (67.2%) | 296 (67.6%) | 253 (66.9%) |
| – Heterozygous (CT) | 139 (39.2%) | 130 (29.7%) | 115 (30.4%) |
| – Homozygous (CC) | 12 (2.6%) | 12 (2.7%) | 10 (2.7%) |
n (%) or mean (SD).
HRT: Hormone replacement therapy.